Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Blood thinners in AFib: how the decision is made

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Anticoagulation is the treatment that most changes what happens to someone with AFib. It is also the one people are most inclined to stop, because the benefit is invisible and the inconvenience is not.

The decision is individualised, and understanding how it is made makes it easier to live with.

Related pages: Atrial fibrillation (AFib)

The bottom line

What we know
  • Risk is estimated from specific risk factors, not from symptoms or episode frequency.
  • DOACs are first-line for most people; warfarin is right in specific situations.
  • Anticoagulants substantially cut stroke risk and modestly raise bleeding risk.
  • Aspirin is not an adequate substitute for people who need anticoagulation.
  • Never start, stop, pause or change dose without medical advice.
What is still open
  • How to manage people at high risk of both stroke and bleeding.
  • Whether brief device-detected AFib warrants anticoagulation.
  • How long to continue after a successful ablation.

The story, step by step

  1. 1. The risk score ()
  2. 2. The medicines ()
  3. 3. The trade-off ()
  4. 4. Taking them safely ()
  5. 5. If you cannot take them ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

How the decision starts

Review of many studies

What happens

Counting risk factors.

What the research shows

  • Clinicians use a scoring system, most commonly CHA2DS2-VASc, to estimate annual stroke risk from risk factors rather than from how AFib feels.
  • The factors are congestive heart failure, hypertension, age 75 or older, diabetes, prior stroke or TIA, vascular disease, age 65 to 74, and female sex. Prior stroke and older age count double.
  • A higher total means higher annual stroke risk, and above a threshold the expected benefit of anticoagulation outweighs the expected bleeding harm for most people.
  • At a score of zero in men, treatment is generally not advised. In the middle, it is a genuine discussion.
  • The score is a starting point, not a verdict. Other factors, including kidney function, atrial size, and what the person values, all feed in.
  • The same score applies whether AFib is paroxysmal, persistent or permanent.

Why it matters

Asking what your score is, and what it implies, is a reasonable and useful question, and it makes the recommendation much easier to engage with.

What's still uncertain

  • How to improve risk prediction beyond the current scores.
  • Why some low-score patients still have strokes.

Read more

Next: The medicines

Part 2 of 5

DOACs and warfarin

Review of many studies

What happens

What is actually prescribed.

What the research shows

  • Direct oral anticoagulants, including apixaban, rivaroxaban, edoxaban and dabigatran, are first-line for most people with AFib.
  • They do not need routine blood-level monitoring, have fewer food interactions than warfarin, and work within hours.
  • Dosing depends on kidney function, age and weight, so kidney function is checked at the start and periodically afterwards.
  • Warfarin remains the correct choice in specific situations, including mechanical heart valves and some rheumatic mitral valve disease, and for some people with severe kidney impairment.
  • Warfarin requires regular INR blood tests and a consistent vitamin K intake, which means keeping green vegetable intake steady rather than avoiding it.
  • Reversal treatments exist for both warfarin and the DOACs, which matters in the event of serious bleeding or emergency surgery.

Why it matters

Neither class is simply better. The right one depends on valves, kidneys, other medicines and what fits the person's life.

What's still uncertain

  • How the DOACs compare with each other directly.
  • How to dose safely in advanced kidney disease.

Read more

Next: The trade-off

Part 3 of 5

Stroke risk against bleeding risk

Review of many studies

What happens

What is actually being balanced.

What the research shows

  • Anticoagulants substantially reduce ischemic stroke and modestly increase bleeding, including a small increase in bleeding into the brain, which is lower with DOACs than with warfarin.
  • For most people with meaningful stroke risk, the arithmetic favours treatment, because an AFib stroke is typically more disabling than a treated bleed.
  • Bleeding risk is assessed formally, but a high bleeding score is mainly a prompt to fix what is modifiable rather than to withhold the drug.
  • Modifiable contributors include uncontrolled blood pressure, heavy alcohol use, avoidable use of NSAIDs such as ibuprofen, and unstable INR on warfarin.
  • Falls are a common worry. For most people the stroke risk prevented outweighs the risk from falls, though this deserves individual discussion in frail patients.
  • Previous bleeding, anaemia, kidney or liver disease, and certain other medicines all feed into the assessment.

Why it matters

Bleeding concerns are legitimate and are best handled by naming them in the appointment, because several of the contributors can be reduced.

What's still uncertain

  • How to weigh falls risk against stroke risk in frail patients.
  • How much of the bleeding risk is genuinely modifiable.

Read more

Next: Taking them safely

Part 4 of 5

Adherence and everyday precautions

Review of many studies

What happens

Where the real-world risk lies.

What the research shows

  • Missing doses matters more with DOACs than with warfarin, because they clear from the body within about a day. A gap leaves a window with little protection.
  • Take them at the same time daily, use a pill organiser or alarm, and ask what to do about a missed dose before it happens rather than guessing.
  • Do not run out. Order repeat prescriptions early, and carry a few days' supply when travelling.
  • Avoid NSAIDs such as ibuprofen and naproxen unless your clinician has agreed to them, because they add bleeding risk and can affect the kidneys.
  • Tell every dentist, surgeon, pharmacist and clinician that you take an anticoagulant, and never pause it for a procedure without asking the prescriber.
  • Use a soft toothbrush and an electric razor, take care with knives and sharp tools, and report unusual bruising, black stools, blood in the urine, or prolonged bleeding.
  • After any significant head injury, seek medical assessment the same day even if you feel completely well.

Why it matters

Carry something that identifies you as taking an anticoagulant, and keep a current medicine list on your phone or in your wallet.

What's still uncertain

  • How best to support long-term adherence.
  • Whether reminder technology changes outcomes.

Read more

Next: If you cannot take them

Part 5 of 5

Closing the pouch

Review of many studies

What happens

An option when anticoagulation is not possible.

What the research shows

  • Some people cannot take anticoagulants long-term, usually because of recurrent serious bleeding.
  • In that situation, a device can be placed inside the left atrial appendage through a catheter from a vein in the leg, sealing off the pouch where most clots form.
  • A short course of medicine is usually needed after the procedure while the device seals over, then it is often possible to stop.
  • The appendage can also be removed or closed surgically if the chest is being opened for another operation.
  • These options are not a routine alternative for people who could take an anticoagulant, and availability varies by centre.
  • They reduce but do not eliminate stroke risk, because a minority of clots form elsewhere.

Why it matters

If bleeding has made anticoagulation impossible, this is a specific question worth raising with a cardiologist or electrophysiologist.

What's still uncertain

  • How closure devices compare with modern DOACs.
  • Who benefits most from closure.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.